RE:RE:RE:TLT is slowly starting to MOVE into that SWEET SPOT! SF, where do you see us in a year with all you know and with your best estimate? And I know you do not have a crystal ball however, given this exchange, how high can we reasonably expect to go here? Can something on this exchange exceed the $7-10 range or is it necessary to uplist? I realize I'm asking a favor here which you do not have any obligation to answer. I hope you will though because I respect and try to digest everything you meticulously craft here. Do you see a JV, buyout, or a go it alone scenario? Will big pharma truly tolerate a complete paradigm treatment shift in an area they have no expertise in? My gut tells me they do not have an appetite for reinventing their way of doing business on the fly. Merck seems to be very intentional about finding a way to keep Keytruda at the forefront no matter what although Keytruda could be piggybacked with1433 right? It would be very helpful to understand how you see this playing out. I am a student of all you say and of your research and appreciate it as much as anyone here. So even if you do not wish to answer I am thankful just the same. Thank you